Matrix metalloproteinase-2 functional promoter polymorphism G1575A is associated with elevated circulatory MMP-2 levels and increased risk of cardiovascular disease in systemic lupus erythematosus patients

Abstract

Matrix metalloproteinase-2 (MMP-2) is a zinc dependent endonuclease that degrades type IV collagen, the major structural component of basement membranes. MMP-2 functional promoter polymorphism G1575A affects circulating level of MMP-2 and may be considered an important genetic determinant of cardiovascular disease (CVD) in systemic lupus erythematosus (SLE) patients. In this study, association between MMP-2 1575A allele with serum MMP-2, neopterin and lipid-lipoprotein levels and with SLE and developing CVD was investigated.

The present case–control study consisted of 109 SLE patients with and without CVD (mean age, 35.6 years) and 101 gender- and age-matched, unrelated, healthy controls (mean age, 37.1 years) from the population in the west of Iran. MMP-2 1575G/A polymorphism was detected by polymerase chain reaction (restriction fragment length polymorphism) PCR-RFLP, serum MMP-2, neopterin and lipid levels were determined by enzyme-linked immunosorbent assay (ELISA), high-performance liquid chromatography (HPLC) and enzyme assay, respectively.

The presence of MMP-2 G1575A allele was found to be associated with SLE and developed CVD (OR = 1.78, p = 0.029 and OR = 3.43, p = 0.025, respectively). The SLE patients with MMP-2 A (G/A + A/A) allele had higher MMP-2 activity (301 ± 166 vs. 194 ± 35.5, p = 0.002), neopterin (29.4 ± 39.4 vs. 7.3 ± 4.6, p = 0.005), LDL-C (120 ± 25.7 vs. 87 ± 39.3, p = 0.045) and lower HDL-C (39.6 ± 11 vs. 45.9 ± 11.8, p = 0.031) levels than the control subjects. There was a significantly positive correlation between MMP-2 level with neopterin, total cholesterol and TG levels and negative correlation with HDL-C level in SLE patients with CVD.

MMP-2 G1575A allele may be a risk factor for SLE. The carriers of this allele have high levels of MMP-2, neopterin, total cholesterol and TG and lower levels of HDL, thus, they are more likely to develop heart disease.

Keywords

Cardiovascular disease matrix metalloproteinase-2 MMP-2 concentration neopterin genetic polymorphism lipid profile lupus nephropathy blood pressure

Get full access to this article

View all access options for this article.

References

Jacobsen

Petersen

Ullman

. Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus. Scand J Rheumatol 1999; 28: 75–80.

Bellomip

Spindler

Lucero

. Systemic lupus erythematosus: mortality and survival in Argentina. A multicenter study. Lupus 2000; 9: 377–381.

Ward

. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 338–346.

Plazak

Gryga

Dziedzic

. Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study. Arthritis Res Ther 2011; 13: R117–R117.

Wallberg-Jonsson

Ohman

Dahlqvist

. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997; 24: 445–451.

Farber-Elman

Sthoeger

Tcherniack

Dayan

Mozes

. Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol 2002; 127: 393–398.

Kvalvik

Jones

Symmons

. Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. Scand J Rheumatol 2000; 29: 29–37.

Zhang

Herrmann

. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999; 99: 1788–1794.

Gibbons

Dzau

. The emerging concept of vascular remodelling. N Engl J Med 1994; 330: 1431–1438.

10.

Galis

Khatri

. Matrix metalloproteinases in vascular remodeling and atherogenesis. The good, the bad, and the ugly. Circ Res 2002; 90: 251–262.

11.

Saedi

Vaisi-Raygani

Khaghani

. Matrix metalloproteinas-9 functional promoter polymorphism 1562C>T increased risk of early-onset coronary artery disease. Mol Biol Rep 2012; 39: 555–562.

12.

Gai

Zhang

Liang

. MMP-2 and TIMP-2 gene polymorphisms and susceptibility to atrial fibrillation in Chinese Han patients with hypertensive heart disease. Clinica Chimica Acta 2010; 411: 719–724.

13.

Füth

Dinh

Nickl

. Soluble P-selectin and matrix metalloproteinase 2 levels are elevated in patients with diastolic dysfunction independent of glucose metabolism disorder or coronary artery disease. Exp Clin Cardiol 2009; 14: e76–e79.

14.

Chang

Lin

Tsay

. Elevated circulatory MMP-2 and MMP-9 levels and activities in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Biochem 2008; 41: 955–959.

15.

Rodriguez-Lopez

Perez-Pampin

Gomez-Reino

Gonzalez

. Regulatory polymorphisms in extracellular matrix protease genes and susceptibility to rheumatoid arthritis: a case-control study. Arthritis Res Ther 2006; 8: R1–R1.

16.

Vasku

Goldbergova

Holla

Siskova

Groch

. A haplotype constituted of four MMP-2 promoter polymorphisms (y1575GyA, y1306CyT, y790TyG an dy735CyT) is associated with coronary triple-vessel disease. Matrix Biology 2004; 22: 585–591.

17.

Alp

Menevse

Tulmac

Yilmaz

Yalcin

Cengel

. The role of matrix metalloproteinase-2 promoter polymorphisms in coronary artery disease and myocardial infarction. Genet Test Mol Biomarkers 2011; 15: 193–202.

18.

Pasterkamp

Schoneveld

Hijnen

. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metaloproteases-1, -2 and -9 in the human coronary artery. Atherosclerosis 2000; 150: 245–253.

19.

Noji

Kajinami

Kawashiri

. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med 2001; 39: 380–384.

20.

Hojo

Ikeda

Ueno

Arakawa

Shoimada

. Expression of matrix metalloproteinases in patients with acute myocardial infarction. Jap Circ J 2001; 65: 71–75.

21.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

22.

Gladman

Ginzler

Goldsmith

Fortin

Liang

Urowitz

. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363–363.

23.

Carru

Zinellu

Sotgia

. A new HPLC method for serum neopterin measurement and relationships with plasma thiols levels in healthy subjects. Biomed Chromatogr 2004; 18: 360–366.

24.

Elizabeth

Flavall

Elizabeth

. Dissociation of neopterin and 7,8-dihydroneopterin from plasma components before HPLC analysis. J Chromatography B 2008; 863: 167–171.

25.

Vaisi-Raygani

Rahimi

Tavilani

Pourmotaabed

. Butyrylcholinesterase K variant and the APOE-epsilon4 allele work in synergy to increase the risk of coronary artery disease especially in diabetic patients. Mol Biol Rep 2010; 37: 2083–2091.

26.

Harendza

Lovett

Panzer

Lukacs

Stahlrf

. Linked Common Polymorphisms in the Gelatinase A Promoter Are Associated with Diminished Transcriptional Response to Estrogen and Genetic Fitness. J Biol Chem 2003; 2789: 20490–20499.

27.

Clark

Swingler

Sampieri

Edwards

. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 2008; 40: 1362–1378.

28.

Price

Greaves

Watkins

. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 2001; 276: 7549–7558.

29.

MacNaul

Chartrain

Lark

. Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinase-1 in rheumatoid synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression. J Biol Chem 1990; 265: 17238–17245.

30.

Zhang

McCluskey

Fujii

. Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-α, granulocyte-macrophage CSF, and IL-1β through prostaglandin-dependent and-independent mechanisms. J Immunol 1998; 161: 3071–3076.

31.

Goetzl

Banda

Leppert

. Matrix metalloproteinases in immunity. J Immunol 1996; 156: 1–4.

32.

Kieffer

Giummelly

Schjoth

. Activation of metalloproteinase-2, loss of matrix scleroprotein content and coronary artery calcification. Atherosclerosis 2001; 157: 251–254.

33.

Guo

Shi

Liu

Sun

Chi

. Rosuvastatin Inhibits MMP-2 Expression and Limits the Progression of Atherosclerosis in LDLR-deficient Mice. Arch Med Res 2009; 40: 345–351.